The population pharmacokinetics of panipenem was studied in 23 neonates. Their postconceptional age (PCA) was 24.7-42.6 weeks and their body weight was 530-4455 g at initiation of therapy. Panipenem was infused over a period of 60 min in a dose of 10.2-34.7 mg/kg bd in 21 patients, tid in one patient and four times daily in one patient for a mean of 10.7 days. Blood samples were obtained just before the infusion and 1-2 h after and again 6 h after the infusion. 
Introduction
Bacterial infection causing neonatal sepsis and low birth weight in neonates are important factors affecting both mortality and long-term morbidity. These factors have resulted in the increasing use of broad-spectrum antibiotics such as carbapenems in the neonatal intensive care unit. Panipenem, a drug used in combination with betamipron, is one of the injectable carbapenem antibiotics developed in Japan. Concomitant iv doses of betamipron reduce the nephrotoxicity of panipenem without any change in the pharmacokinetic parameters. 1 Panipenem/betamipron is used for the treatment of severe infections and sepsis because of its wide antibacterial activity against both Grampositive and -negative bacteria. The Ministry of Health and Welfare, Japan, approved its use for infectious paediatric diseases, and neonatologists use it empirically for neonates. Although panipenem/betamipron is an important antibiotic for the neonatal intensive care unit owing to the high-risk situation, there are no published data on the pharmacokinetics of panipenem in the neonatal population, because of its chemical instability. Various changes in renal function and body composition with increases in the postconceptional age (PCA) in neonates make the pharmaco- We have developed a method to measure the serum concentration of panipenem, and the non-linear mixed-effect model (NONMEM with first-order method), population pharmacokinetic program 2 was used to assess the intra-and inter-individual variabilities in neonates.
51
This study was conducted in order to determine the population pharmacokinetic parameters and the various indices of maturation in neonates of various PCA. Furthermore, the correct dosage of panipenem/betamipron for neonates was evaluated.
Materials and methods

Patients
Patients with clinically suspected or confirmed severe infection in the neonatal intensive care unit at the Kitasato University Hospital, Japan, were eligible for participation in this study. The study group comprised 23 patients (13 females, 10 males) and the patients' PCA ranged from 24.7 to 42.6 weeks, with a mean (Ϯ S.D.) of 31.8 (Ϯ 6.3) weeks at the time of therapy initiation. The mean patient weight was 1.5 Ϯ 1.2 kg. The serum creatinine (Scr) concentration was 0.9 Ϯ 0.6 mg/dL. Table I shows the patient characteristics. Informed consent was obtained from the parents of the patients.
Dosing and sampling procedures
Panipenem/betamipron (Carbenin; Sankyo Co., Ltd, Tokyo, Japan) was infused over 60 min using a syringe pump at a dose of 10-20 mg/kg given bd (actual dosages were between 10.2 and 34.7 mg/kg; mean 18.6 Ϯ 5.3 mg/kg). The dose recommendation was based on the paediatric dosage; 30-60 mg/kg divided into three times a day, which the Ministry of Health and Welfare, Japan, approved. The mean duration of the treatment was 10.7 Ϯ 5.7 days ranging over 3-28 days in this study. Blood samples obtained by capillary heel prick were drawn just before the infusion 1-2 h post-infusion, and again 6 h after the infusion, for determination of panipenem concentrations. This sampling strategy was applied twice: on the third and sixth day of panipenem therapy, at least in principle.
52
Panipenem concentrations in serum were determined by high-performance liquid chromatography using a Multisolvent Delivery System 600 (Nihon Waters K.K., Tokyo, Japan) as follows: detector, UV-970 (Jusco Co., Ltd, Tokyo, Japan); wavelength, 300 nm; column, ODS-2 (GL Science Co., Ltd, Tokyo, Japan); mobile phase, 35% (v/v) methanol in 5 mM sodium phosphate buffer containing 5 mM dodecylsulphate sodium salt (pH 5.8) at a flow rate of 0.8 mL/min. Panipenem is a very unstable antibiotic in solution; therefore, 10 L of MOPS [200 mM 3-(N-morpholino)propanesulphonic acid] was added to 10 L of the plasma sample as a stabilizer immediately after blood sampling. The lower limit of quantification was 0.5 mg/L. A linear regression analysis of the standard curve from 6.25 to 100 mg/L yielded the following equation: y ϭ 0.11126 ϫ Ϫ0.0075 (r ϭ 1.000). The coefficient of variation (CV%) of within-runs and between-runs for the assay of panipenem were less than 2.5 and 2.7%, respectively. The recoveries of panipenem were 98.4%. (Panipenem was a gift from Sankyo Co., Ltd, Tokyo, Japan.)
Data analysis
The concentration-time study and the physiological data analysis were performed using the NONMEM with firstorder method software (double precision NONMEM Version V, Level 1.0) on a PC/AT computer operating under Windows 95 (Microsoft Co., Ltd, Tokyo, Japan).
The pharmacokinetic model of the individual serum panipenem concentrations was examined by the oneand two-compartment models using an ADVAN1 and ADVAN3 supplied PREDPP subroutine, part of the NONMEM program. The design of the one-compartment model (ADVAN1) allowed determination of the components of the population mean parameters, the panipenem clearance (CL) and the volume of distribution (V) of the panipenem. The two-compartment model (ADVAN3) determined CL, the central volume of distribution (V c ), the intercompartmental clearance (Q) and the peripheral volume of distribution (V p ) of the panipenem.
Proportional interindividual variability models were invoked for each clearance and the volume of distribution as follows:
in which C ϳ L and V ϳ are the population parameters; CL and V are random variables with a mean of zero and a variance of 2 ; CL i and V i are the individualized estimated parameters.
The additive error model was used for residual variability:
in which C ij is the ith measured serum panipenem concentration in the jth individual, C ij * is the estimated serum panipenem concentration, as observed for the pharmacokinetic data, and ε ij is the independently identical distributed statistical error with a mean of zero and a variance of ␦ 2 .
Effects of patient characteristics on the population mean value
In the fitting process using the one-compartment model, many covariates were evaluated as follows for the influence on the population mean values for the CL of the panipenem: PCA, gestational age (GA), postnatal age (PNA), Apgar score, body weight (BW) and Scr.
CL ϭ 1 ϩ 2 ϫ physiological factor where 1 and 2 are the intercept and slope parameters. The glomerular filtration rate (GFR) standardized for body weight correlated strongly with the inverse of the Scr, so that the equation below was used in the pharmacokinetic model.
CL ϭ 1 ϩ 2 ϫ BW/Scr
Coulthard 3 and Al-Dahhan et al. 4 reported that GFR in infants shows a logarithmic rise with PCA so that an exponential model was also used in the pharmacokinetic model.
Because the maturation of GFR in infants is increasing from a PCA of 34 to 35 weeks, the differences in the CL for a PCA Ͻ or у 32, 33, 34 and 35 weeks were also used in the pharmacokinetic model.
The volume of distribution was assessed by the equation shown below. V ϭ 1 ϫ physiological factor where the physiological factor was either PCA, GA, PNA or BW.
During the regression of the above equations, NON-MEM computes the estimates of the population parameters and the standard error for all samples, and this standard error can be used to define the confidence intervals for the true parameter values. NONMEM provides the minimum value of the objective function (negative value of twice the log-likelihood difference: Ϫ2 l.l.d.) in this regression. The changes in the objective function Ͼ6.635 were determined to be significant ( 2 , degree of freedom ϭ 1, P Ͻ 0.01) based on a 2 distribution with 1 degree of freedom. A P value Ͻ0.01 was considered to be statistically significant. Based on these results, all significant factors were used to construct the full regression equation. After deletion of each factor in the full model, the objective function value of this reduced model was compared with the full model. The final estimates of the population pharmacokinetic parameters of panipenem were then defined.
Retrospective evaluation of a panipenem dosage for neonates
Based on the NONMEM analysis, we simulated a concentration-time curve with the use of one-compartment parameter estimates and compared that simulation with that of the parameters in a Phase I multiple dose study, 5 which we re-analysed using NONMEM. The Phase I study was conducted in nine healthy adult male volunteers who received 500 or 1000 mg of panipenem by constant iv infusion for 60 min every 12 h for 5 days. The Phase I study was comparable and had a study design similar to our study; it was concluded that 2000 mg panipenem daily was well tolerated and safe.
Results
The serum concentration-time curve of panipenem for all subjects (23 cases; 108 serum concentrations) is shown in Figure 1 . No specific findings that indicated the toxicity of panipenem were detected. All cases were analysed for the pharmacokinetic parameters by various factors. The two-compartment parameters were as follows: CL ϭ 0.150 L/h, V c ϭ 0.54 L, Q ϭ 0.014 L/h and V p ϭ 0.28 L. One-compartment parameters were CL ϭ 0.175 L/h and V ϭ 0.55 L. The two-compartment model described the population mean significantly better than the onecompartment model (P Ͻ 0.01). However, further analysis to estimate the covariates for CL is not possible using the two-compartment model owing to the lack of samples, and the two-compartment model is inherently much more difficult to use in a clinical situation, so that the modelbuilding process was conducted with only the one-compartment model.
Hypothesis testing for the pharmacokinetic parameters of the panipenem is summarized in Table II BW, inverted Scr and (exponential) PCA were selected for the full regression analysis. In the preliminary analyses, the formula of the CL with PCA was not an important factor when PCA and BW were analysed at the same time. It should be noted that PCA also showed a very strong correlation with BW (r ϭ 0.88). We surveyed the quantitative relationship between the three kinds of full model for CL. Statistically significant parameters were added to the full regression model, and each parameter was eliminated from the full model (Table III) .
First, the full regression model 1 for the estimated CL and V was as follows:
The full regression model 1 using the above factors for the fixed effect showed that only BW was found to significantly affect CL (P Ͻ 0.001) and V (P Ͻ 0.001) (OBJ ϭ 478.539). The effect of BW on CL for у33 weeks of PCA and on V was significant in the full model 3.
The final model using PCA and BW was examined, and the final regression equations, parameter estimates and 95% confidence intervals are shown in Table IV . The final equations for full-term PCA were CL ϭ 0.00176 ϫ exp 0.141 ϫ PCA (L/h) and V ϭ 0.53 ϫ BW (L). The interindividual variability (CV%) of CL and V was 26.9% and 29.0%, respectively. The standard deviation in the intraindividual variability was determined to be 4.3 mg/L. Other final equations from the group of divided terms of PCA were CL ϭ 0.0832 (PCA Ͻ 33), CL ϭ 0.179 ϫ BW (PCA у 33) and V ϭ 0.53 ϫ BW (L). The interindividual variability (CV%) of CL and V was 23.9 and 28.5%, respectively. The standard deviation of the intraindividual variability was determined to be 4.2 mg/L.
Fitting performance using population means
To evaluate the predictive performances of the population parameters, we also obtained the individual Bayesian estimates of clearance and the volume of distribution of panipenem in these patients using the POSTHOC option in the NONMEM software package. The derived pharmacokinetic parameter of panipenem in this study was evaluated by the distribution against the linear regression of the predicted versus the observed serum panipenem concentrations ( Figure 5 ).
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Retrospective evaluation of the panipenem dosage for neonates
The population means of the re-analysis for the data in the Phase I multiple-dose study were as follows: CL ϭ 14.1 L/h and V ϭ 13.1 L. The simulation of the concentration-time curve with the use of the Phase I study was compared with that of the parameters in neonates: CL ϭ 0.175 L/h, V ϭ 0.55 L. The plot assumes a 10 or 20 mg/kg dose given to a 1.5 kg neonate every 12 h, and 500 mg or 1000 mg of panipenem given to an adult by constant iv infusion for 60 min every 12 h ( Figure 6 ).
Discussion
Previous studies show that the values of PCA, serum creatinine and BW are very important factors when determining the initial panipenem dosing regimen in neonates. Panipenem is stable against the renal brush border enzyme, dehydropeptidase-1 (DHP-1), but it still exists as a metabolite (R-976-2) in the urine. 6 Panipenem and R-976-2 are almost totally excreted with the urine. Therefore, the factors affecting the clearance of panipenem are thought to be (i) the inactivity by DHP-1 in the renal brush border, (ii) the extrarenal pathway of panipenem metabolism, 7 and (iii) the glomerular filtration, reflecting the same results as the 'pharmacokinetics of imipenem-cilastatin in neonates', report. 8 Clinically, renal function is the most important factor, because the area under the concentration-time curve of panipenem in patients with severe renal dysfunction (creatinine clearance Ͻ 30) was apparently increased compared with that in those with a moderate renal dysfunction. 9 For these reasons, the maturation of GFR and systemic renal function are the most important factors in estimating the CL. There are many studies of the developmental changes with PCA and GA in the renal function of neonates. Fawer et al. 10 and Arant 11 reported that the rate of rise of GFR in infants with gestational age has been shown to increase immediately from 34 to 35 weeks. Coulthard 3 has also reported that the rate of glomerular maturation has been shown to increase steeply with an increase in the PCA from 34 to 35. Also, there was no difference between babies of up to 1 week of postnatal age and older babies. Based on this association, it is suggested 57 that the proposed adjustment in the initial dosage regimen for panipenem be based on PCA. When we evaluated CL by the NONMEM analysis, we found that the mean CL of the patients with PCA Ͻ 33 weeks was significantly lower than that of the patients with a PCA у 33 weeks, and CL showed a logarithmic rise with PCA. Many reports support our conclusion that CL is correlated strongly with PCA. In the final analysis, CL in a patient over 33 weeks PCA was strongly correlated with BW, but we could not find any significant covariates related to CL in a group with PCA Ͻ 33 weeks. In a group with PCA Ͻ 33 weeks, the 5 min values of the Apgar score also did not correlate with CL. In the very low birth weight neonates, especially for a PCA Ͻ 33 weeks, it is very difficult to estimate the maturation of renal function and CL, because of the high interpatient variability and rapid changes in the renal function. Arant 11 has also described previously that renal maturation and improving GFR appear to correlate best with PCA, but there was a high degree of interpatient variation and a relative lack of maturation in the functional capacity of the kidney in infants with a PCA of Ͻ 34 weeks.
Based on the final analysis of this research, the population means analysed showed a good predictive performance. Distribution of the plot versus the CL formula line displays a bilateral symmetry around the regression so that the observed population mean was assumed to be an unprejudiced parameter.
When we attempted to determine the correct dosage of antibiotics, the time above MIC, peak concentration and area under the concentration-time curve are the major parameters correlating with efficacy. In a neonatal intensive care unit, nosocomial infections are an important cause of morbidity and mortality. Infections due to Listeria spp., group B -haemolytic streptococci, Gram-negative bacilli and methicillin-resistant staphylococci all have a high mortality. We compared neonatal pharmacokinetic parameters with adult parameters. Based on the simulated concentrations for neonates and adults, the predicted concentrations in neonates resulted in an adequate serum concentration. Actually, we observed the 1 h serum concentrations of 18.59-54.90 mg/L and mean trough concentrations of 1.15-9.45 mg/L with a mean dosage of 18.6 Ϯ 5.3 mg/kg given every 12 h. The peak concentrations observed were similar to those of most adult populations and the trough concentrations did not become too high even in the group with PCA Ͻ 33 weeks. The AUC in neonates was greater than in adults.
All patients tolerated panipenem therapy very well. In conclusion, we recommend a dosage for neonates of 10-20 mg/kg administered bd. Further studies are needed for neonates from the group with a PCA of Ͻ 33 weeks and specific populations such as neonates with intrauterine growth retardation. 
